HANNAH PRICE: Open Payments
NPI 1407354277 · PETAL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 103 payments from 17 companies in 2025. Trend: 2023 $1,343 · 2024 $1,518 · 2025 $1,519
Food & beverage: $1,519
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $285 |
| Galderma Laboratories, L.P. | 15 | $264 |
| GENZYME CORPORATION | 9 | $195 |
| UCB, Inc. | 18 | $171 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| PFIZER INC. | 5 | $86 |
| LEO Pharma Inc. | 3 | $80 |
| Organon LLC | 5 | $61 |
| REVANCE THERAPEUTICS, INC. | 3 | $61 |
| Janssen Biotech, Inc. | 2 | $57 |
Products named: DUPIXENT, NEMLUVIO, Bimzelx, RINVOQ, SKYRIZI, CIBINQO, DAXXIFY, TREMFYA.
Industry payments across MS — which companies pay providers there.
